Shilpa Medicare gets Health Canada GMP approval for Jadcherla facility

Karnataka: Shilpa Medicare has recently announced that the Company's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana, has received Health Canada GMP approval.

The inspection was conducted from September 12, 2022, to September 16, 2022.

The facility is involved in the manufacturing, packaging, labelling, and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy.

This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada.

"This approval reaffirms the company's focused efforts to maintain the GMP status up to the standards of global regulatory authorities," Shilpa Medicare said in a BSE filing.

Read also: Shilpa Medicare Hyderabad division gets USFDA clearance